Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies.

Cancer research - 15 Dec 2005

MacFarlane Marion, Kohlhaas Susan L, Sutcliffe Michael J, Dyer Martin J S, Cohen Gerald M

Abstract excerpt

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its agonistic antibodies, which are currently in early clinical trials for treating various malignancies, induce apoptosis through triggering of either TRAIL-R1 or TRAIL-R2. Based on studies using agonistic monoclonal antibodies, we recently proposed that primary chronic lymphocytic leukemic cells seem to signal apoptosis primarily through...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Caspase 8
Share to Caspases
Share to Fas-Associated Death Domain Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Lymphocytic, Chronic, B-Cell

Share to Lymphoma, Mantle-Cell

Share to Receptors, TNF-Related Apoptosis-Inducing Ligand

Share to Receptors, Tumor Necrosis Factor

Share to TNF-Related Apoptosis-Inducing Ligand

Source

Identifiers

PMID: 16357130
DOI: 10.1158/0008-5472.CAN-05-2801

Genes

HGS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies.PMID 16357130Read ↗

Therapeutic applications of TRAIL receptor agonists in cancer and beyondSemantic proximity Read ↗

The TRAIL apoptotic pathway in cancer onset, progression and therapy.Semantic proximity Read ↗

Involvement of Protective Autophagy in TRAIL Resistance of Apoptosis-defective Tumor CellsSemantic proximity Read ↗

Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling.Semantic proximity Read ↗

The TRAIL of oncogenes to apoptosisSemantic proximity Read ↗

TRAIL-R1-targeted chimeric antigen receptor T cells exhibit dual antitumor effectsSemantic proximity Read ↗

TRAIL/Apo-2-ligand-induced apoptosis in human T cellsSemantic proximity Read ↗

A Novel Paradigm to Trigger Apoptosis in Chronic Lymphocytic LeukemiaSemantic proximity Read ↗

TRAIL as a target in anti-cancer therapy.Semantic proximity Read ↗

CD70-restricted specific activation of TRAILR1 or TRAILR2 using scFv-targeted TRAIL mutants.Semantic proximity Read ↗

Rapid and efficient cancer cell killing mediated by high-affinity death receptor homotrimerizing TRAIL variants.Semantic proximity Read ↗

Mutations Enhancing Selectivity of Antitumor Cytokine TRAIL to DR5 Receptor Increase Its Cytotoxicity against Tumor Cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.